Ardern-Jones Audrey, Kenen Regina, Lynch Elly, Doherty Rebecca, Eeles Rosalind
The Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK.
The College of New Jersey, Department of Sociology and Anthropology, New Jersey, USA.
Hered Cancer Clin Pract. 2010 Jan 12;8(1):1. doi: 10.1186/1897-4287-8-1.
Women from families with a high risk of breast or ovarian cancer in which genetic testing for mutations in the BRCA1/2 genes is inconclusive are a vulnerable and understudied group. Furthermore, there are no studies of the professional specialists who treat them - geneticists, genetic counsellors/nurses, oncologists, gynaecologists and breast surgeons.
We conducted a small qualitative study that investigated women who had developed breast cancer under the age of 45 and who had an inconclusive BRCA1/2 genetic diagnostic test (where no mutations or unclassified variants were identified). We arranged three focus groups for affected women and their close female relatives - 13 women took part. We also interviewed 12 health professionals who were involved in the care of these women.
The majority of the women had a good grasp of the meaning of their own or a family member's inconclusive result, but a few indicated some misunderstanding. Most of the women in this study underwent the test for the benefit of others in the family and none mentioned that they were having the test purely for themselves. A difficult issue for sisters of affected women was whether or not to undertake prophylactic breast surgery. The professionals were sensitive to the difficulties in explaining an inconclusive result. Some felt frustrated that technology had not as yet provided them with a better tool for prediction of risk.
Some of the women were left with the dilemma of what decision to make regarding medical management of their cancer risk. For the most part, the professionals believed that the women should be supported in whatever management decisions they considered best, provided these decisions were based on a complete and accurate understanding of the genetic test that had taken place in the family.
来自乳腺癌或卵巢癌高风险家族的女性,若对其进行BRCA1/2基因的突变检测结果不明确,她们是一个易受伤害且研究不足的群体。此外,目前尚无关于治疗她们的专业人员——遗传学家、遗传咨询师/护士、肿瘤学家、妇科医生和乳腺外科医生的研究。
我们开展了一项小型定性研究,调查了45岁以下患乳腺癌且BRCA1/2基因诊断检测结果不明确(未发现突变或未分类变异)的女性。我们为受影响的女性及其亲密女性亲属安排了三个焦点小组,共有13名女性参与。我们还采访了12名参与这些女性护理工作的卫生专业人员。
大多数女性很好地理解了自己或家庭成员检测结果不明确的含义,但少数人表示存在一些误解。本研究中的大多数女性进行检测是为了家庭中的其他人,没有人提到她们进行检测纯粹是为了自己。受影响女性的姐妹面临的一个难题是是否进行预防性乳房手术。专业人员对解释检测结果不明确的困难很敏感。一些人感到沮丧的是,技术尚未为他们提供更好的风险预测工具。
一些女性在如何就癌症风险的医疗管理做出决策方面陷入了两难境地。在很大程度上,专业人员认为,无论女性做出何种他们认为最佳的管理决策,只要这些决策基于对家族中进行的基因检测的全面准确理解,都应该给予支持。